3 hours ago
1
alexsl
Shares of Gossamer Bio (NASDAQ:GOSS) traded higher on Wednesday after UBS upgraded the California-based biotech to Buy from Neutral, citing an “underappreciated” late-stage data catalyst related to the company’s lead asset, seralutinib.
The upgrades come at a time when a
© FBT Company 2025. All rights are reserved
English (US) ·